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Abstract: Pulmonary arterial hypertension (PAH) describes a rare, progressive vascular disease caused
by the obstruction of pulmonary arterioles, typically resulting in right heart failure. Whilst PAH
most often manifests in adulthood, paediatric disease is considered to be a distinct entity with
increased morbidity and often an unexplained resistance to current therapies. Recent genetic studies
have substantially increased our understanding of PAH pathogenesis, providing opportunities
for molecular diagnosis and presymptomatic genetic testing in families. However, the genetic
architecture of childhood-onset PAH remains relatively poorly characterised. We sought to investigate
a previously unsolved paediatric cohort (n = 18) using whole exome sequencing to improve the
molecular diagnosis of childhood-onset PAH. Through a targeted investigation of 26 candidate
genes, we applied a rigorous variant filtering methodology to enrich for rare, likely pathogenic
variants. This analysis led to the detection of novel PAH risk alleles in five genes, including the
first identification of a heterozygous ATP13A3 mutation in childhood-onset disease. In addition,
we provide the first independent validation of BMP10 and PDGFD as genetic risk factors for PAH.
These data provide a molecular diagnosis in 28% of paediatric cases, reflecting the increased genetic
burden in childhood-onset disease and highlighting the importance of next-generation sequencing
approaches to diagnostic surveillance.
Keywords: exome sequencing; molecular genetics; lung disease; paediatrics; pulmonary
arterial hypertension
1. Introduction
Pulmonary arterial hypertension (PAH) is an uncommon vascular disorder that remains incurable
despite significant advances in current treatment regimens. PAH is characterised by obstruction and
occlusion of the pulmonary arterioles leading to progressive pulmonary arterial pressure overload,
right ventricular hypertrophy and failure of the right side of the heart [1]. Typical histopathological
features of PAH include marked vascular remodelling of the pulmonary arterioles as a consequence
of exuberant proliferation of pulmonary artery endothelial (PAEC) and smooth muscle (PASMC)
cells. In families, PAH predominantly segregates as an autosomal dominant trait displaying features
Genes 2020, 11, 1328; doi:10.3390/genes11111328 www.mdpi.com/journal/genes
Genes 2020, 11, 1328 2 of 12
of complex disease, namely variable expressivity, reduced penetrance and a gender bias favouring
females [2]. Despite major advances in delineating PAH aetiology, the associated morbidity and early
mortality burden of this disease remains perniciously high, with an average life expectancy of 3–5 years
from diagnosis [3].
Paediatric PAH represents a clinically distinct form of disease. Although less prevalent, at an
estimated 4.8–8.1 cases/million [4,5], than the adult form (15–50 cases/million) [6], childhood-onset PAH
(cPAH) is marked by greater morbidity, depressed responses to therapy and poor survival metrics [7,8].
Taken together, these features suggest a specific genetic background. Putatively causal genetic variants
have been described in at least 26 PAH risk genes [9–14], of which deleterious variation in BMPR2,
encoding a type II receptor of the transforming growth factor beta (TGF-beta) superfamily, was firmly
established as the major risk factor in adult PAH [13]. In paediatric cases, rare deleterious mutations of
BMPR2 and other key components of the bone morphogenetic protein (BMP) signalling pathway have
been determined to be rare causal factors. These include the receptor proteins activin A receptor-like
type 1 (ACVRL1, encoding ALK1), BMPR1B and endoglin (ENG), as well as GDF2 (encoding the
ligand BMP9) and the cytoplasmic signalling mediator SMAD9 [8,15–20].
Whole exome sequencing (WES) has been instrumental in the accelerated gene discovery in PAH,
notably in genetic risk unrelated to the canonical BMP pathway. Moreover, these findings both
expanded the mutation spectrum in cPAH and shed light on the epidemiology of this discrete disease
entity. For example, mutations within the transcription factor genes T-box 4 (TBX4) and SRY-box 17
(SOX17) show enriched contribution to paediatric PAH compared to adult-onset, explaining up to 7.7%
and 3.3% of paediatric cases, respectively [8,21,22]. Of note, SOX17 mutations show a strong correlation
to PAH associated with congenital heart disease in both adult and paediatric disease [22,23]. More recent
findings include loss-of-function variants in the ATP-binding cassette subfamily C member 8 (ABCC8)
gene and in the endothelial cell-specific ligand BMP10 [24,25], whilst genome-wide gene burden
approaches in predominantly adult cohorts identified the candidate risk genes ATPase 13A3 (ATP13A3),
fibulin 2 (FBLN2) and platelet-derived growth factor D (PDGFD), among others [10,14]. These novel
gene discoveries demonstrated the benefit of a granular approach to the genomic interrogation of
discrete case cohorts.
While these data further developed the molecular architecture of PAH, the mutational landscape
remains relatively poorly understood in paediatric cohorts, particularly for more recently reported
genes [10,12]. Here, we sought to investigate a previously unsolved paediatric cohort, first, to better
define the mutational background of cPAH, and second, to augment the existing body of data
underlying this disease. Taken together, this study highlights the hitherto undefined role of ATP13A3
in the pathogenesis of paediatric PAH and, importantly, provides independent validation of putative
gene-disease associations in BMP10 and PDGFD.
2. Materials and Methods
2.1. Patient Cohort and Clinical Assessment
Eighteen unrelated patients and their relatives were recruited from specialist PAH centres in the
UK and the Netherlands. Ethical approval for the study was received from local ethics review boards
and written informed consent was obtained from all participants or their legal guardian. The study
was conducted in accordance with the Declaration of Helsinki, and the protocol was approved by the
St Thomas’ Hospital Research Ethics Committee (08/H0802/32).
Clinical diagnoses were established by PAH specialists in accordance with the classification of the
World Symposium on Pulmonary Hypertension [26]. All patients previously underwent conventional
genetic screening for BMPR2, ACVRL1 and ENG, and were found to be mutation-negative [16,27].
Following pedigree analysis and clinical examination, patients were classified as having either idiopathic
PAH (IPAH; n = 8), PAH associated with congenital heart disease (APAH-CHD; n = 7) or heritable
PAH with one or more affected relatives (HPAH; n = 3).
Genes 2020, 11, 1328 3 of 12
2.2. Exome Sequencing
Genomic DNA was extracted from peripheral blood using standard methodologies. Whole exome
sequencing for all probands was performed by Novogene Ltd. Briefly, exome libraries were captured
using the SureSelect Human All Exon kit (Agilent Technologies, Santa Clara, CA, USA), and enriched
fragments underwent paired-end sequencing on an Illumina platform. Quality control filtration of raw
FASTQ files discarded read pairs containing adapter contamination and those with <80% of base calls
achieving a Phred score of Q30. Sequence alignment to human reference genome assembly GRCh37 was
undertaken using Burrows–Wheeler Aligner [28] and Picard MarkDuplicates (Genome Analysis Tool
Kit (GATK), Broad Institute, Cambridge, MA, USA) was used to flag PCR duplicate reads for removal.
GATK (v3.8) software was used for single nucleotide variant (SNV) and insertion and deletion (indel)
detection [29]. Variant annotation was performed using ANNOtate VARiation (ANNOVAR) [30].
2.3. Candidate Gene Analysis
Annotated WES profiles for each patient were screened for rare, deleterious variants in 26
established and emerging PAH risk genes: ABCC8, ACVRL1, AQP1, ATP13A3, BMP10, BMPR1B,
BMPR2, CAV1, EIF2AK4, ENG, EVI5, FBLN2, GDF2, GGCX, KCNA5, KCNK3, KDR, KLF2, KLK1,
NOTCH3, PDGFD, SMAD1, SMAD4, SMAD9, SOX17 and TBX4. Rare variants were defined as those
with a minor allele frequency of ≤1 in 10,000 (MAF ≤ 0.0001), as reported in the Genome Aggregation
Database control population (gnomAD v2.1.1; https://gnomad.broadinstitute.org). Splice region
and exonic variants with likely functional consequences (nonsense, frameshift, nonframeshift indels
and missense SNVs) were retained. Copy number variants were not considered in the analysis
presented herein. The functional impact of missense variants was informed by in silico pathogenicity
predictions. Specifically, variants with a Combined Annotation Dependent Depletion (CADD) score of
≥20 (https://cadd.gs.washington.edu) were considered potentially causal [31]. Additional evidence for
pathogenicity was obtained from observing at least one deleterious score across Sorting Intolerant
from Tolerant (SIFT; ≤0.05), PolyPhen-2 (≥0.909) and MutationTaster2 (annotation “disease causing”)
algorithms [32–34]. The location of each variant was inspected for correlation with conserved protein
domains, providing further confirmation of likely pathogenicity.
Candidate variants were visualised and inspected for artefacts using Integrative Genomics Viewer
(IGV) to exclude false positives [35,36]. All identified variants were validated in an independent sample
by Sanger sequencing (Eurofins Genomics, Ebersberg, Germany) and tested for familial co-segregation
where DNA samples were available.
3. Results
3.1. WES Analysis of the cPAH Cohort
Overall, 92% of base calls achieved a mean quality score of Q30. A mean depth of coverage of
65x (range: 54x–78x) was achieved for all samples, with an average of 91% (range: 86–94%) of bases
achieving >20x coverage. Manual inspection of all PAH risk genes using IGV confirmed sufficient
coverage of ≥10x across all exonic regions and intron–exon boundaries.
A targeted variant analysis of previously reported risk genes in our panel of childhood-onset IPAH,
APAH and HPAH patients revealed putatively pathogenic missense variants in ABCC8, ATP13A3,
BMP10, PDGFD and SMAD9 (Table 1). All variants were validated by Sanger sequencing. Based on
our exclusion criteria, no other likely causal variants in the reported PAH risk genes were identified in
these patients.
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Table 1. Variants Identified in Childhood-Onset Pulmonary Arterial Hypertension.
Patient Sex Age ofOnset Diagnosis Variant Identified
Mutation
Category
GnomAD
MAF
Variant
Identifier(s)
CADD
Score
SIFT
Score
PolyPhen2
(HumVar)
Mutation
Taster
P1 M 9 y APAH–CHD(ASD)
ATP13A3 (exon 11)
NM_024524.4
c.1148C>A
(p.Thr383Lys)
Missense * - Novel 32 0.001, D 0.991, D 1.0, D
P2 F 3 y IPAH
BMP10 (exon 1)
NM_014482.3
c.247G>A
(p.Glu83Lys)
Missense 0.000009
dbSNP:
rs1192957334; Not
in ClinVar
28 0.047, D 0.999, D 1.0, D
P3 F <5 y IPAH
PDGFD (exon 4)
NM_025208.5
c.550G>A
(p.Glu184Lys)
Missense -
dbSNP:
rs769639743; Not
in ClinVar
28.2 0.007, D 0.980, D 0.9998, D
P4 M 19 m IPAH
ABCC8 (exon 7)
NM_000352.6
c.1069G>A
(p.Val357Ile)
Missense 0.000018
dbSNP:
rs771392416; Not
in ClinVar
23 0.235, T 0.042, B 1.0, D
P5 F 4.5 y HPAH (motheralso affected)
SMAD9 (exon 6)
NM_001127217.3
c.1117G>A
(p.Val373Ile)
Missense 0.00013
dbSNP:
rs140504903;
ClinVar:
VCV000311894
27 0.001, D 0.936, D 1.0, D
APAH–CHD: PAH associated with congenital heart disease; ASD: atrial septal defect; B: benign; CADD: Combined Annotation Dependent Depletion; D: damaging (SIFT), probably
damaging (PolyPhen2) or disease causing (Mutation Taster); IPAH: idiopathic pulmonary arterial hypertension; HPAH: heritable pulmonary arterial hypertension; MAF: minor allele
frequency in gnomAD v2.1.1 (controls); m: months; SIFT: Sorting Independent from Tolerant; T: tolerated; y: years. * The ATP13A3 missense variant in Patient 1 is located within the
consensus splice region.
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3.2. Novel Association of ATP13A3 with Paediatric APAH-CHD
We identified a novel missense variant in ATP13A3 (c.1148C>A, p.Thr383Lys) in a male child
with APAH–CHD. To the best of our knowledge, this represents the first finding of a molecular defect
in this risk gene in a paediatric case. The patient was diagnosed with PAH at nine years of age,
associated with a secundum atrial septal defect (Figure 1A). All in silico predictions were consistent
with a high probability of pathogenicity (Table 1). Parental samples were not available to conduct
familial segregation analysis.
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Figure 1. Sequence chromatograms and familial segregation of identified variants in childhood-onset
pulmonary arterial hypertension (cPAH). (A) Patient 1 has a c.1148C>A missense mutation in ATP13A3;
(B) Patient 2 has a heterozygous BMP10 c.247G>A mutation; (C) Patient 3 is heterozygous for a
c.550G>A mutation in PDGFD; (D) Patient 4 has a c.1069G>A missense variant in the ABCC8 gene;
(E) Patient 5 carries a heterozygous SMAD9 c.1117G>A missense variant, which co-segregates with the
disease (+/−) in his affected mother and maternal grandfather, who is an obligate carrier. Unaffected
family members available for testing are all wild-type (WT). The horizontal line underlines the mutated
codon. * DNA sample not available.
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PAH clinical setting, provides the first independent confirmation of BMP10 as a PAH risk gene [25].
All bioinformatic predictions were consistent with a high likelihood of pathogenicity (Table 1).
Familial co-segregation analysis confirmed the unaffected mother was wild-type but, as no DNA was
available from the father, it was not possible to determine whether this variant had arisen de novo in
the proband (Figure 1B).
PDGFD is a newly identified risk gene in PAH [14]; this analysis offers the first independent
validation of its causal association with PAH, as well as confirming a specific role in the development
of paediatric disease through the identification of a rare missense variant (c.550G>A, p.Glu184Lys) in a
female cPAH patient (Figure 1C). The variant, which is not present in population control databases,
gave a CADD score of 28.2 and was predicted to be deleterious by all three missense prediction
algorithms (Table 1).
A heterozygous missense variant in ABCC8 (c.1069G>A, p.Val357Ile), novel in the context of PAH,
was observed in a male patient diagnosed at 19 months of age (Figure 1D). While the CADD score
and MutationTaster prediction were strongly indicative of a deleterious impact, the conclusions of
pathogenicity based on other in silico markers were ambiguous, likely due to the interchangeability
of valine and isoleucine residues at this position across related proteins in lower organisms (Table 1).
Unavailability of parental DNA samples precluded familial segregation analysis of the PDGFD and
ABCC8 variants.
3.4. Analysis of HPAH Samples Identifies a Potential Molecular Defect of SMAD9
An examination of WES data from the three HPAH probands revealed a missense variant in
SMAD9 (c.1117G>A, p.Val373Ile) in a single family. Following a diagnosis of PAH, the proband died at
five years of age. The affected amino acid residue displays high conservation across species, reflected in
high deleterious scores across all in silico prediction algorithms employed (Table 1). Co-segregation
was confirmed in two affected family members and an obligate carrier (Figure 1E). In addition,
the candidacy of this variant as a causal defect in PAH was underpinned by the same finding in an
HPAH patient reported in the ClinVar database (SCV000384082). However, as an observed allele
frequency of >0.0001 in European controls exceeded our threshold for inclusion, this was resultantly
considered to be a variant of unknown significance (VUS) in the absence of compelling functional data.
4. Discussion
This study applied a targeted 26 gene analysis to WES data in a European paediatric cohort,
elucidating candidate molecular mechanisms in five patients to further illuminate the genetic
architecture of early-onset PAH. It must be noted that all candidate variants presented in this
analysis were categorised as variants of unknown significance in accordance with American College of
Medical Genetics and Genomics (ACMG) guidelines [37], including those that met our criteria as being
highly deleterious. Evidence of variant pathogenicity derived from population frequency, bioinformatic
predictions and the biological relevance of these genes to PAH pathology is considered herein.
While ATP13A3 was recently identified and functionally characterised as being causative in adult
PAH [10], this study is the first to implicate heterozygous variation of ATP13A3 in paediatric-onset
cases. The gene encodes a P-type ATPase for which the substrate specificity and biological role remain
poorly defined [38], but is a known transmembrane protein that localises to endosomal compartments
and is likely involved in polyamine transport, key molecules for cell growth and proliferation [39,40].
Recent functional work demonstrated that ATP13A3 mRNA is expressed in PASMCs, whilst loss
of ATP13A3 inhibits endothelial cell proliferation and increases apoptosis, consistent with disease
initiation models in PAH [10]. The novel c.1148C>A (p.Thr383Lys) variant identified in this study
alters a highly conserved amino acid residue located within the actuator domain, which functions
to dephosphorylate the catalytic phosphorylation domain (Figure 2). The variant is predicted to
disrupt splicing and result in nonsense-mediated decay. Although molecular defects in the ATP13A3
gene clearly underlie susceptibility to PAH [10,12,20,41], the mechanism of pathogenicity remains
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to be defined. Further functional analyses are therefore warranted to elucidate whether ATP13A3
loss-of-function represents a molecular mechanism independent to the BMP signalling pathway, and
thus a new therapeutic target.
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published reports [38,40]. Likely pathogenic PAH mutations (CADD ≥ 15) reported in the literature
are indicated by the filled grey circles [10,12,20,41]. The c.1148C>A (p.T383K) mutation identified in
this study is highlighted by the gold star and is located a jacent to a previously reported splice-region
variant [10]. Numbers indicate a ino acid positions at each end of the 10 transmembrane domains.
The red triangles denote e sential aspa agin residues (D498: ctive c talytic site; D883, D 87: Mg2+
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The WES analysi workflow in this study i e t fi 10 c.247G>A (p.Glu83Lys)
missense variant with consistent in silico arker i it . he residue is highly conserved
across species and is located within the conserve tide domain, where a BMP10
no sense muta ion was previously identified in c [ . servation su ports a cumulating
evidence implicating BMP10 los -of-functi i t is [ ,42]. BMP10 encodes a high
affinity ligand that activates the ALK1 and B 2 e ot elial cell s rface receptor within the BMP
signalling pathway [43]. The gene product shares 65 a ino acid sequence identity with its BMP9
paralogue, encoded by the GDF2 gene. GDF2 variant enrichment was recently reported in three
large PAH cohorts, strongly implicating the BMP9/BMP10/ALK1/BMPR2 signalling pathway in PAH
pathobiology [10,12,20]. Both in vitro and in vivo studies propose a model where BMP9 and BMP10 act
interchangeably and with compensatory functionality via ALK1 to regulate endothelial cell migration
and proliferation, maintaining endothelial quiescence [44,45]. Based on evidence of sequence homology,
mature peptide structural similarities and reported functional redundancy of these gene products, it is
proposed that the BMP10 missense variant reported here may have a similar pathogenic mechanism to
those observed in GDF2; further exploration on both the genetic and functional level is now warranted.
PDGFD missense variants were recently associated with PAH pathogenesis in a case-control
analysis of a large, combined cohort [14]. The identification of a novel c.550G>A (p.Glu184Lys) variant
of this gene in the cPAH panel analysed here serves to establish PDGFD as a contributing factor to
childhood disease and provides independent validation of the discovery study. PDGF family signalling
pathways play important roles in vascular pathologies, including mediation of remodelling processes
that are known to occur in PAH [46]. The plausibility of this gene contributing to PAH risk is further
enhanced by cell-type-specific gene expression studies using single cell RNA-seq data, demonstrating
high expression i endothelial cells within heart and lung tissue, a key site of disease potentiation in
PAH [14]. Of interest, PDGFD presents an exciti g drug-targeting candidate, with studies of the tyrosine
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kinase inhibitor imatinib, a known pharmacological inhibitor of PDGF signalling, demonstrating
15-fold reductions in PDGFD expression in cardiac tissue [47] and suppression of medial thickening
via receptor inhibition in patient-derived in vitro PASMC models [48].
The novel c.1069G>A (p.Val357Ile) missense variant identified in ABCC8 describes an amino
acid substitution in the highly conserved transmembrane domain 1 of the mature and functionally
important SUR1 product. This finding supports previous investigations that indicate pathogenic
variation in ABCC8 underlies 2–5% of PAH cases, including 10 previous reports of paediatric-onset
cases [8,12,24]. The gene encodes the SUR1 subunit of KATP potassium channels located in cardiac
smooth muscle cells. Of note, the variant identified in this study was previously reported to cause
hyperinsulinism in compound heterozygosity with a second ABCC8 allele, although without any
clinical signs of PAH [49]. Whole cell electrophysiology and radium efflux assays of reported missense
variants have demonstrated loss of KATP channel activity [24]. Taken together, these data suggest that
loss of SUR1-dependent channel function represents a pathogenic mechanism in PAH, although the
primary physiological role remains unknown. These findings are of clinical pertinence, as ABCC8 is
considered a possible therapeutic target wherein impaired KATP activity could be pharmacologically
rescued in vitro using diazoxide, a selective potassium-channel opening drug [24]. This may have
further implications for the development of diazoxide-induced pulmonary hypertension in children
with hyperinsulinaemic hypoglycaemia [50,51].
The SMAD9 c.1117G>A (p.Val373Ile) variant detected in an HPAH case in this study is predicted
to be deleterious by in silico analysis, further supported by familial co-segregation and its location
with the C-terminal Mad Homology 2 (MH2) domain, a region of extensive evolutionary conservation.
SMAD1, SMAD4 and SMAD9 encode signalling intermediaries that act as downstream mediators of the
BMPR2 pathway. Variants in SMAD9 were previously identified in three patients [17,52,53], and were
recently validated in both adult-onset and paediatric PAH [12,20,22]. Functional analyses of the
impact of SMAD9 variants on SMAD-mediated signalling demonstrated impaired responses to ligand
stimulation and reduced transcriptional activation of the downstream BMP target gene, ID2 [17,52].
Although this variant was deemed a VUS based on our minor allele frequency threshold boundary,
it is noteworthy that it was previously detected in an independent patient with PAH. This speaks to
the challenges of setting an appropriate MAF cut-off when investigating rare diseases, especially in
the context of notable reduced penetrance. Whereas most studies consider an approximation of
disease allele frequency equivalent to population disease prevalence, inheritance-based calculations
derived from Hardy–Weinberg equilibrium with adjustment for nonpenetrant alleles may be a more
appropriate method to avoid false negative findings.
5. Conclusions
Taken together, these findings provide data supporting wider locus heterogeneity of paediatric
PAH than previously reported and expand the allelic series of variation in known cPAH genetic
risk factors. This study supports the inclusion of these genes in screening panels in future work
for diagnostic surveillance of paediatric cases. In particular, we provide independent validation of
the recently identified risk factors BMP10 and PDGFD, and the first report of an ATP13A3 variant
in a paediatric case, warranting further analysis of understudied cellular pathways key to PAH
pathogenesis. Notably, although novel gene detection was beyond the scope of this study in the context
of extensive locus heterogeneity, this report emphasises the importance of the rigorous analysis of
well-defined case cohorts to delineate the molecular basis of cPAH as a framework for future gene
discovery initiatives.
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